Medicinal product designation for TB-403 for medulloblastoma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ONCURIOUS NV, an emerging oncology company focused on the development of innovative orphan drugs for the treatment of pediatric tumors, announced that the European Commission has confirmed the orphan drug designation for TB-403 for medulloblastoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login